Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

◆ TRIAL DATA

In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. (ESMO Open)